- Home
- PBYI vs CMPX Comparison
PBYI vs CMPX Comparison
Compare PBYI & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- CMPX
- Stock Information
- Founded
- PBYI 2010
- CMPX 2014
- Country
- PBYI United States
- CMPX United States
- Employees
- PBYI N/A
- CMPX N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- PBYI Health Care
- CMPX Health Care
- Exchange
- PBYI Nasdaq
- CMPX Nasdaq
- Market Cap
- PBYI 164.3M
- CMPX 291.8M
- IPO Year
- PBYI N/A
- CMPX N/A
- Fundamental
- Price
- PBYI $3.54
- CMPX $2.78
- Analyst Decision
- PBYI Strong Buy
- CMPX Strong Buy
- Analyst Count
- PBYI 1
- CMPX 9
- Target Price
- PBYI $7.00
- CMPX $12.67
- AVG Volume (30 Days)
- PBYI 306.9K
- CMPX 929.9K
- Earning Date
- PBYI 07-31-2025
- CMPX 08-11-2025
- Dividend Yield
- PBYI N/A
- CMPX N/A
- EPS Growth
- PBYI 143.51
- CMPX N/A
- EPS
- PBYI 0.77
- CMPX N/A
- Revenue
- PBYI $232,709,000.00
- CMPX $850,000.00
- Revenue This Year
- PBYI N/A
- CMPX N/A
- Revenue Next Year
- PBYI N/A
- CMPX N/A
- P/E Ratio
- PBYI $4.64
- CMPX N/A
- Revenue Growth
- PBYI 2.68
- CMPX N/A
- 52 Week Low
- PBYI $2.23
- CMPX $0.77
- 52 Week High
- PBYI $4.13
- CMPX $4.08
- Technical
- Relative Strength Index (RSI)
- PBYI 58.61
- CMPX 68.90
- Support Level
- PBYI $3.26
- CMPX $2.50
- Resistance Level
- PBYI $3.65
- CMPX $2.71
- Average True Range (ATR)
- PBYI 0.14
- CMPX 0.19
- MACD
- PBYI 0.01
- CMPX 0.01
- Stochastic Oscillator
- PBYI 84.78
- CMPX 87.14
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.